Clinical Pharmacognosy Lab., Department of Pharmacy Practice, WHO/PAHO Collaborating Centre for Traditional Medicine, College of Pharmacy, University of Illinois at Chicago, IL 60612, United States.
Pharmacogenomics Lab., Department of Biosciences, Barkatullah University, Bhopal, Madhya Pradesh 462026, India.
Curr Drug Discov Technol. 2021;18(1):95-104. doi: 10.2174/1570163817666200127112928.
Purified fractions from a Boswellia serrata Roxb. Ex. Colebr. (Burseraceae) extract (ETOH and DCM) contain biologically active compounds that are well known for having inflammation inhibitory properties. In this work, the purified fractions were tested in-vitro for LTC, LTA and COX-2 activities using ELISA and qPCR was performed to determine gene regulation in human leukemia (HL-60) Cells. Two D-imaging tomography was performed to determine the anti-inflammatory activities of the fractions in BALB/c mouse model of lung inflammation.
To evaluate anti-inflammatory activities of bioactive compounds of Boswellia serrata purified fractions.
In-vitro MTT assay was performed in HL-60 cell lines for measuring the toxicity/ viability of the cells. ELISA tests were performed for evaluating LTA, LTC and COX-2 activities. qPCR was performed to evaluate the expression of mRNA in HL-60 cells. In-vivo experiments were performed in OVA sensitized and challenged BALB/c mice at two doses of Boswellia serrata purified fraction containing 6% Boswellic acid of 50 and 100mg/kg body weight were given orally and the standard drug dexamethasone (DXA, 4 mg/kg body weight) and reduction in lung inflammation was assessed by using an IVIS Xenogen in-vivo fluorescence imaging system.
A purified fraction of Boswellia serrata ETOH extracts reduced leukotriene-C-synthase activity by 52%, leuktotriene-A-hydrolase activity by 22% and COX-2 activity by 99% with an IC50 of 12.5μg/ml. Intragastric administration of the purified fraction of Boswellia serrata at two doses of 50mg/kg b.w. and 100mg/kg b.w., respectively along with 2-3% HPMC resulted in a ~51% (P value <0.01) reduction in OVA induced lung inflammation in BALB/c mice as observed by imaging tomography. Treatment of the OVA challenged mice with standard drug dexamethasone (DXA) reduced inflammation by ~66% with significant value (P<0.0001).
The present study describes that Boswellia serrata ethanolic extracts purified fraction (ETOH-BS) possess significant anti-inflammatory activities in HL-60 and in BALB/c and further supports for its use as Ayurvedic medicines traditionally in the treatment of lung disorders including allergy and asthma.
从乳香树（乳香树科）提取物（ETOH 和 DCM）中分离的纯化部分含有具有抑制炎症特性的生物活性化合物。在这项工作中，使用 ELISA 测试了纯化部分在体外对 LTC、LTA 和 COX-2 活性的抑制作用，并通过 qPCR 测定了人白血病（HL-60）细胞中的基因调控。使用 BALB/c 小鼠肺部炎症模型进行了两次 D 成像断层扫描，以确定该分数的抗炎活性。
评估乳香树纯化部分生物活性化合物的抗炎活性。
在 HL-60 细胞系中进行体外 MTT 测定，以测量细胞的毒性/活力。进行 ELISA 测试以评估 LTA、LTC 和 COX-2 活性。通过 qPCR 评估 HL-60 细胞中 mRNA 的表达。在卵清蛋白（OVA）致敏和挑战的 BALB/c 小鼠中进行体内实验，以两种剂量（50 和 100mg/kg 体重）口服给予含有 6%乳香酸的乳香树纯化部分，并用 IVIS Xenogen 体内荧光成像系统评估标准药物地塞米松（DXA，4mg/kg 体重）和肺部炎症的减少。
乳香树 ETOH 提取物的一种纯化部分将白三烯 C 合酶活性降低了 52%，白三烯 A 水解酶活性降低了 22%，COX-2 活性降低了 99%，IC50 为 12.5μg/ml。以 50mg/kg b.w.和 100mg/kg b.w.的两种剂量口服给予乳香树纯化部分以及 2-3% HPMC，可使 BALB/c 小鼠中由 OVA 诱导的肺部炎症减少约 51%（P 值<0.01），如成像断层扫描所示。用标准药物地塞米松（DXA）治疗 OVA 挑战的小鼠可使炎症减少约 66%，具有显著意义（P<0.0001）。
本研究表明，乳香树乙醇提取物纯化部分（ETOH-BS）在 HL-60 和 BALB/c 中具有显著的抗炎活性，并进一步支持其作为阿育吠陀药物传统上用于治疗包括过敏和哮喘在内的肺部疾病。
